Want to see OLMA full AI Analyst Report?
Top Page
Olema Pharmaceuticals
(NASDAQ:OLMA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.50
▼(-31.26% Downside)
Action:Reiterated
Date:10/13/26
Overall score is held back primarily by lack of revenue, widening losses, and sustained cash burn despite a low-debt balance sheet. Technicals also reflect strong recent downside momentum, while valuation is difficult to assess on earnings due to negative profitability and no dividend support.
Positive Factors
Low Leverage
Extremely low leverage gives Olema meaningful financial flexibility while it funds clinical development. The limited debt burden reduces fixed obligations and refinancing exposure, allowing more capital to remain available for research, trials, and potential commercialization.
Negative Factors
No Commercial Revenue
Zero revenue confirms that Olema remains dependent on clinical progress rather than an established commercial product base. Until a program reaches market, operating resources must be funded without recurring product sales, leaving future revenue timing highly dependent on development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Extremely low leverage gives Olema meaningful financial flexibility while it funds clinical development. The limited debt burden reduces fixed obligations and refinancing exposure, allowing more capital to remain available for research, trials, and potential commercialization.
Read all positive factors
Olema Pharmaceuticals (OLMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$560.86M
Dividend YieldN/A
Average Volume (3M)1.37M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth-10.16%
CountryUS
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.12
Shares Outstanding87,497,604
10 Day Avg. Volume1,447,831
30 Day Avg. Volume1,368,359
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.78K
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$33.17Price Target Upside204.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.39
Revenue Forecast (FY)$2.25M
Olema Pharmaceuticals Business Overview & Revenue Model
Company Description
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the ...
Olema Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -204.12M | -161.96M | -129.08M | -96.28M | -104.43M | -70.93M |
| Net Income | -204.57M | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
Balance Sheet | ||||||
| Total Assets | 486.58M | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Cash, Cash Equivalents and Short-Term Investments | 461.07M | 505.44M | 434.09M | 261.81M | 204.42M | 287.25M |
| Total Debt | 660.00K | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Total Liabilities | 56.01M | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Stockholders Equity | 430.56M | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
Cash Flow | ||||||
| Free Cash Flow | -164.74M | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
| Operating Cash Flow | -164.74M | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Investing Cash Flow | -99.54M | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Financing Cash Flow | 260.40M | 211.30M | 268.82M | 133.41M | 476.00K | 1.39M |
Olema Pharmaceuticals Technical Analysis
Negative
10.91
Price Trends
9.21
Negative
10.22
Negative
14.55
Negative
Market Momentum
-0.73
Negative
25.48
Positive
30.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLMA, the sentiment is Negative. The current price of 10.91 is above the 20-day moving average (MA) of 7.57, above the 50-day MA of 9.21, and below the 200-day MA of 14.55, indicating a bearish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 25.48 is Positive, neither overbought nor oversold. The STOCH value of 30.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OLMA.
Olema Pharmaceuticals Risk Analysis
Olema Pharmaceuticals disclosed 92 risk factors in its most recent earnings report. Olema Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Olema Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $884.56M | 12.12 | 284.38% | ― | 948.35% | ― | |
62 Neutral | $477.32M | 38.42 | 1.91% | ― | -15.05% | ― | |
52 Neutral | $223.65M | -3.05 | -21.40% | ― | -93.55% | -1143.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $560.86M | -3.02 | -48.22% | ― | ― | -10.16% | |
43 Neutral | $58.69M | -0.21 | 108.75% | ― | 32.43% | 7.41% | |
42 Neutral | $137.05M | -1.83 | -38.71% | ― | ― | 10.44% |
* Healthcare Sector Average
OLMA
Olema Pharmaceuticals
6.41
-2.38
-27.08%
MGTX
Meiragtx Holdings
9.21
0.34
3.83%
ARVN
Arvinas Holding Company
7.30
-2.35
-24.35%
GOSS
Gossamer Bio
9.61
-181.60
-94.98%
KROS
Keros Therapeutics
11.28
-3.75
-24.95%
CMPX
Compass Therapeutics
0.76
-3.35
-81.48%
Olema Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Olema Pharmaceuticals Names New Chief Financial Officer
Positive
Aug 13, 2026
On August 13, 2026, Olema Pharmaceuticals announced that it had appointed veteran biotech finance executive Jason O’Byrne as chief financial officer, effective August 11, 2026, with the board’s approval granted on July 28, 2026. The cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.